Ulinastatin treatment for severe abdominal infection
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether the drug ulinastatin can reduce inflammation in patients with severe abdominal infections. It may help improve recovery by controlling the body's immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a severe abdominal infection in the last 48 hours.
- You have symptoms like fever, belly pain, or swelling, and imaging or other tests confirm the infection.
- You have a certain level of organ dysfunction (measured by a score called SOFA of 2 or more).
- You do not have severe immune system problems, active cancer, or other serious conditions listed in the trial rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if N-acetylcysteine, a medicine that helps the liver and fights inflammation, can improve outcomes for adults with a severe infection and liver stress.
This trial tests an experimental drug called NAI for people in the intensive care unit (ICU) with severe infections like sepsis. It aims to boost your immune system to help fight the infection and improve recovery.
This trial tests whether a fluid called Gelaspan (a gelatin-based IV fluid) is better for treating sepsis patients who need emergency abdominal surgery than standard crystalloid fluids. It checks if you have a belly infection and high lactate levels, and you must not have serious heart, lung, or kidney problems.
This trial tests whether adding ursodeoxycholic acid (a bile acid supplement) to standard sepsis treatment can reduce inflammation and organ damage. It aims to improve recovery in adults with sepsis.
This Phase 2 study tests whether Pentaglobin®, a blood-product made from immune proteins, helps critically ill people with severe abdominal infection (peritonitis) after the infection source is surgically cleaned up. It targets patients with signs of strong inflammation and severe illness.
This study looks at how certain natural molecules in your blood might affect recovery from severe infections or sepsis. By understanding these molecules, doctors hope to better predict outcomes and personalize treatment for patients in the ICU.
Hear when a new Systemic Inflammatory Response trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.